Potential Contribution of a Novel Antifibrotic Factor, Hepatocyte Growth Factor, to Prevention of Myocardial Fibrosis by Angiotensin II Blockade in Cardiomyopathic Hamsters

Yoshiaki Taniyama(The University of Osaka), Toshio Ogihara(Osaka University), Ryuichi Morishita(The University of Osaka), Hironori Nakagami(Osaka Health Science University), ShokeiKim(Osaka City University), Kunio Matsumoto(Kanazawa University), Toshikazu Nakamura(The University of Osaka), Hiroshi Sakonjo(Osaka City University), Atsushi Moriguchi(The University of Osaka), Jitsuo Higaki(Saiseikai Matsuyama Hospital)
Circulation
July 11, 2000
10.1161/01.cir.102.2.246
Cited by 175

Related Papers

Erratum: The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2009)
|Hypertension Research|2014|1.4k
Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis
|The Lancet|2021|997
Hepatocyte Growth Factor Induces Gefitinib Resistance of Lung Adenocarcinoma with Epidermal Growth Factor Receptor–Activating Mutations
|Cancer Research|2008|642
In vivo transfection of cis element “decoy” against nuclear factor- κB binding site prevents myocardial infarction
|Nature Medicine|1997|589
Hepatocyte growth factor gene therapy of liver cirrhosis in rats
|Nature Medicine|1999|588